Background
==========

Many organisms experience stress from natural sources such as territory defense, food competition, resource acquisition and exploration. In humans persistent extreme responses to stressful and anxiety-inducing situations or the inability to cope with such scenarios is a characteristic of an anxiety disorder \[[@B1]\]. Pharmacological studies indicate that anxiety and anxiety-related behaviors are associated with dysregulation of at least one of several major neurotransmitter systems in the brain: serotonergic (serotonin), GABAergic (gamma-aminobutyric acid), catecholaminergic (noradrenaline, dopamine) and glutamatergic (glutmate) systems \[[@B2],[@B3]\]. Efficacies of various anxiolytic compounds, however, vary between individuals (both human and animal models) \[[@B4]\]. The extent to which this can be attributed to the nonselective or pleiotropic molecular aspects of the anxiolytic is unknown.

Selective serotonin reuptake inhibitors (SSRIs) are typically the first-line drugs prescribed for the alleviation of anxiety disorders in humans \[[@B5]\]. SSRI compounds (e.g., fluoxetine, citalopram, sertraline) block the serotonin transporter thus allowing for serotonin levels to remain high for longer periods of time in the synapse. Fluoxetine (tradename: Prozac) is a racemic mixture where both the R and S isomers effectively inhibit the serotonin transporter \[[@B6]-[@B10]\] and has also been demonstrated to have anxiolytic effects in rodents and fish \[[@B11],[@B12]\]. While SSRIs are known to modulate serotonin levels, it has been shown that they also modulate production of neurosteroids (e.g. allopregnanolone) that act as modulators of GABA receptors \[[@B13]-[@B16]\]. In fluoxetine, S-fluoxetine induces greater allopregnanolone production in rodent brains than the R isomer \[[@B6],[@B14]\]. Increasing allopregnanolone levels in rodents has been associated with decreases in aggression and anxiety \[[@B6],[@B15],[@B17]-[@B23]\]. In addition, SSRIs also affect various neuropeptide levels (e.g., neuropeptide Y, oxytocin, arginine vasopressin), which independently can modulate stress and anxiety levels \[[@B24]\]. Our laboratory has shown fluoxetine can affect expression of neuropeptide genes in teleosts \[[@B25]\]. Hence SSRIs appear to affect many systems and understanding the full extent of changes in molecular mechanisms underlying fluoxetine mediated reduction in anxiety and stress is needed.

To understand the mechanisms underlying stress and anxiety, animal models used are highly inbred (i.e., domesticated) or selectively bred to exhibit extreme behavioral and physiological responses to stressful and anxiety-inducing contexts \[[@B2],[@B11],[@B26]-[@B29]\]. Although rodents have been primarily used as animal models for anxiety \[[@B2],[@B26]\], zebrafish (*Danio rerio*) is an emerging system and valuable translational model for understanding stress and anxiety-related behaviors \[[@B30]-[@B35]\]. Similar to rodents, highly inbred lines of zebrafish show differences in baseline levels of stress and anxiety as well as responses to anxiolytics \[[@B2],[@B4],[@B11],[@B12],[@B36],[@B37]\]. Zebrafish share similar neurochemistry, and behavioral and physiological responses to both anxiolytic and anxiogenic drugs as mammals \[[@B11],[@B30],[@B31]\]. Several neurotransmitter systems thought to be modulated in stress and anxiety (e.g., catecholamines, serotonin) in mammals are also described in zebrafish \[[@B32],[@B38],[@B39]\]. Zebrafish possess genes that encode serotonin transporters homologous to those of tetrapods, and the transporters have been shown to transport serotonin across cell membranes and the activity can be reduced with a SSRI *in vitro*\[[@B40]\]. Further, SSRI binding kinetics to the serotonin transporter in teleosts are similar in magnitude to rats \[[@B41]\]. Adult domesticated zebrafish also show reduced anxiety-related behaviors and cortisol levels when treated with fluoxetine \[[@B11]\]. Larval zebrafish treated with fluoxetine show changes in molecular pathways associated with stress response \[[@B42]\], but very little is known of the gene expression changes in adults. Hence, in addition to the zebrafish system's amenability for genetic manipulations and high throughput drug screening \[[@B43]-[@B45]\], the zebrafish represents a powerful model to explore molecular mechanisms of stress and anxiety-related behaviors.

In this study we assess the effects of chronic fluoxetine treatment on behavior and the neural transcriptome of adult wild-derived male zebrafish (High Stationary Behavior line, HSB, \[[@B29]\]). The HSB line shows consistently high levels of stress and anxiety-related behaviors across multiple assays \[[@B29]\]. Given documented stereospecific fluoxetine effects on aggressive behavior and anxiety-mediated neurochemical pathways in rodents \[[@B14],[@B21]\], we test whether anxiety-related behaviors can be modulated stereospecifically in zebrafish by administering racemic, R-fluoxetine, and S-fluoxetine. To analyze the underlying mechanism of fluoxetine-induced anxiolytic effects of behavior, we use RNA-sequencing and test for whole-brain differential expression of protein-coding genes between racemic fluoxetine treatment and control. Through both behavioral and gene expression analyses, we show that fluoxetine alters both behavior and neurogenomic profiles.

Methods
=======

Pharmacological manipulation
----------------------------

Male zebrafish from our selectively bred High Stationary Behavior line (see \[[@B29]\] for line characteristics) were subjected to one of four treatments: a racemic mixture of fluoxetine (n = 30), R-fluoxetine (n = 12), S-fluoxetine (n = 12), or our solvent (water) as a control (n = 42). Studies in other teleosts have shown that waterborne fluoxetine enters the brain and has an approximate half life of nine and three days in the fish and water containing fish, respectively \[[@B46]-[@B48]\]. Testing of the racemic and stereoisomer treatment groups were separated by two months.

The first set of experiments involved treating zebrafish with a racemic fluoxetine mixture or the vehicle control. Treatment duration and racemic fluoxetine concentration follow a previously established protocol \[[@B11]\]. Briefly, fish were chronically treated with 100 μg/L of racemic fluoxetine (Sigma). As it has been previously demonstrated that two weeks of exposure to racemic fluoxetine alters behavior and cortisol levels \[[@B11]\], we assessed whether behavioral changes can be detected on a shorter time scale and thus behaviorally tested fish (n = 12, see below) treated for one week. However, to be consistent with methods in the literature and to make our gene expression results comparable with previous studies, we treated a different set of fish (n = 18) with racemic fluoxetine for two weeks. During treatment, the fish were housed in 2 L tanks in groups of six with constant aeration and fed *ad libitum* daily with commercial food (Tetramin). Every two days, we replaced all of the holding water of the fish with fresh system water (water used for normal housing) containing 100 μg/L racemic fluoxetine. Control fish (n = 42) underwent identical procedures with the exception that the solvent (water) was added to the tanks. For the second set of experiments we administered isomers of fluoxetine and controls to a different set of fish. Fish treated with a stereoisomer of fluoxetine were handled exactly the same way as above, but were treated at a concentration of 33 μg/L for two weeks. As no previous study has administered isomers of fluoxetine in teleosts, our goal was to identify a dose that would maximize the opportunity to observe differences in the behavioral effects of the two isomers in the same manner conducted in rodents \[[@B21]\]. We determined that 33 μg/L is a biologically relevant dose through pilot dose-response analysis where we treated individuals for two weeks as described above but at four different concentrations (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1). We experienced minimal deaths and all fish consumed food during the treatment period, which suggests all were in good health (final sample size: racemic fluoxetine (n = 28), R-fluoxetine (n = 11), S-fluoxetine (n = 11), control (n= 37)).

A subset of fish were treated with racemic fluoxetine (n=18) or water (control, n = 18) but did not undergo behavioral testing. These fish were decapitated and brains removed and stored in RNAlater (Ambion) until processing for either RNA-sequencing or qRT-PCR (see below). The remaining racemic fluoxetine treated fish, those treated with a fluoxetine isomer and control fish were behaviorally tested (see below). All fish used in this study were sexually mature, 7 -- 11 months old, and five generations removed from the wild with the exception of a subset of males used in the qRT-PCR experiment, which were sixth generation.

RNA-sequencing analysis
-----------------------

Using RNA-sequencing, we quantified whole-brain transcriptome levels in male zebrafish (five generations removed from the wild) treated with a racemic mixture of fluoxetine (n = 9) and control animals (n =10). We extracted RNA using RNeasy Plus Mini Kit (Qiagen) according to the manufacturer's protocol. Since we wanted to assess a general effect of fluoxetine on gene expression, we pooled one microgram of total RNA from each individual in a treatment (e.g. one pooled sample for fluoxetine-treated and control fish). RNA quality was assessed with an Agilent 2100 Bioanalyzer (Agilent) and all samples had RNA integrity numbers (RIN) above 8.5. RNA samples were then submitted to the Genomic Sciences Laboratory at North Carolina State University, for cDNA library preparation (TruSeq RNA Sample Prep v2, Illumina) and 72 bp single-end RNA-sequencing (Illumina GAIIx). Following a balanced block design \[[@B49]\], both samples were multiplexed and run across three lanes. During analysis we combined reads across all lanes that passed default quality control filters (Illumina), which generated approximately 30.6 million reads for each of the control and fluoxetine-treated groups. Reads were aligned to the *Danio rerio* genome (assembly Zv9 \[[@B35]\], release 68) using GSNAP \[[@B50]\] with default parameters. We used Cufflinks (ver 2.0.1, \[[@B51]-[@B53]\]) to assess differential expression of protein-coding genes between control and fluoxetine-treated fish employing the program's multi-read and fragment bias correction. We used gProfiler \[[@B54],[@B55]\] to determine significantly over-enriched Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. In Cufflinks and gProfiler we utilized the default false discovery rate (FDR) corrections. Statistical significance was assessed when p~FDR-corrected~ \< 0.05.

Real-time PCR validation analysis
---------------------------------

We assessed the expression of seven genes (*prl2, npy, oxtl, slc6a4a, slc6a4b, slc6a11, ucn3l*) associated with anxiety-like behaviors in other organisms, two genes showing more than two fold differences (*isg15, nrbf2*) in expression between treatments, and one housekeeping gene (*ef1a*) using quantitative reverse transcriptase PCR (qRT-PCR). Of these genes *prl2*, *npy*, *oxtl*, *slc6a11*, *ucn3l*, *isg15*, and *nrbf2* were differentially regulated with RNA-sequencing (see below). We used 12 fish treated with racemic fluoxetine and 12 control fish. Six fish in each treatment group were independent from those used in RNA-seq analysis (six generations removed from the wild). Total RNA from all brains was extracted following the same protocol used for RNA-sequencing preparations (see above). Genomic DNA was removed by column filtration according to manufacturer's protocol (RNeasy Plus Mini kit, Qiagen). We subsequently quantified the RNA using Quant-iT RiboGreen (Invitrogen). Eight microliters of total RNA from each individual was reverse transcribed into cDNA using SuperScript III First-Strand Synthesis System for qRT-PCR (Invitrogen) according to modified manufacturer's protocol where the sample was primed with both random hexamers and oligo(dT)~20~ primers. The cDNA was then purified using Amicon Ultracentrifugal filters (Millipore) according to the manufacturer's protocol \[[@B56]-[@B58]\]. The resulting purified samples were topped off to 100 μl total volume with Nuclease-Free water (Ambion).

The qRT-PCR was run on an ABI 7900HT Fast Real-Time PCR system (Applied Biosystems) using SYBR green detection chemistry (SYBR Select, Applied Biosystems). The primers were designed using Primer-BLAST (NCBI) and primers either spanned exon-exon junctions or the amplicon spanned exons where the intron region was over one kilobase. Each sample was run in triplicate (see Additional file [2](#S2){ref-type="supplementary-material"}: Table S1 for primer sequences, amplicon lengths, and qRT-PCR reaction parameters). We normalized gene expression relative to a housekeeping gene (*ef1a*) and assessed differential expression using commercial software (REST 2009 \[[@B59]\], Qiagen). Our housekeeping gene has been shown to be stable across sex, tissue types, age, and chemical treatment in zebrafish \[[@B60]\]. Normalizing gene expression to total input RNA produced similar results (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S2). We predicted that qRT-PCR results would follow the RNA-sequencing results and assessed and reported significance using one-tail p-values.

Behavioral assay
----------------

Fish exposed to a stereoisomer of fluoxetine and control fish were tested in the Novel Tank Diving Test (NTDT) using established protocols \[[@B11],[@B29]\] to assess changes in anxiety-related behaviors. Briefly, fish were placed in a 15.2 × 27.9 × 22.5 × 7.1 cm (height × top × bottom × width) trapezoidal tank (Aquatic Ecosystems) filled with 1.4 L of system water. We video-recorded the behavior of the fish for six minutes for later analysis using an animal tracking software package (TopScan Lite, Reston, Virginia, USA). Fish treated with racemic mixture of fluoxetine (n = 12) and control fish (n = 12) were tested for five minutes. All fish were five generations removed from the wild. We report latency to enter the top half of the tank, time spent in top half of the tank and stationary time. Stationary time is measured as the amount of time the fish does not exceed a swimming speed of 0.1 cm/sec \[[@B29]\]. For fish that never entered the top half of the tank we set the latency as the length of the trial. All procedures and protocols in this study were approved by the North Carolina State University Institutional Animal Care and Use Committee.

Results and discussion
======================

Fluoxetine reduces anxiety-related behavior but not stereospecifically
----------------------------------------------------------------------

An anxious state is inferred when an animal is placed in an environment where it is conflicted with seeking out potential benefits with that of potential harm (e.g. approach and avoidance) \[[@B2]\]. The approach-avoidance conflict premise is the basis of many common measures of anxiety-related behavioral assays (e.g. open field test, elevated plus maze, light-dark test) \[[@B2],[@B61]\]. In zebrafish one ethologically relevant behavior to potential danger is to swim to the bottom substratum and after the threat has passed, the zebrafish will swim back into the water column. The novel tank diving assay used in this study measures behavioral levels of stress and anxiety-related behaviors in zebrafish by assessing latency to and time spent in the top half of the tank \[[@B11],[@B29]\]. In this study wild-derived zebrafish treated with racemic fluoxetine spent significantly more time in (t = -6.49, p = 2 × 10^-6^) and had a shorter latency to the top half of the tank (t = 8.92, p = 1.38 × 10^-8^) compared to the controls (Figure [1](#F1){ref-type="fig"}A). This suggests that fluoxetine treatment reduced stress and anxiety-related behaviors in male zebrafish. Our data are consistent with published anxiolytic effects of fluoxetine in domestiecated zebrafish and rodents \[[@B11],[@B12]\]. Fluoxetine has also been documented to alter locomotion \[[@B11],[@B12]\], which could confound interpretations of stress and anxiety levels. In this study we did not observe significant differences in locomotion time (i.e. stationary time (t-stat = 1.29, p = 0.21), Figure [1](#F1){ref-type="fig"}A) suggesting that in our experiment the anxiolytic effect of fluoxetine is not likely to be a consequence of reduced ability or motivation to swim.

![**Behavioral measures after drug treatment. A**) Amount of time spent in the top half of the tank, latency to the top half of the tank and stationary behavior for fish treated with racemic fluoxetine (white) or controls (grey). **B**) Amount of time spent in the top half of the tank, latency to the top half of the tank and stationary behavior for fish treated with R isomer (red), S-isomer (brown) or control (grey). Error bars represent standard error. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001.](1471-2164-14-348-1){#F1}

While both isomers reduced stress and anxiety-related behaviors, one was not more potent than the other. There were no significant differences in time spent in the top half of the tank between zebrafish treated with R- or S- fluoxetine (t = 1.47, p = 0.16, Figure [1](#F1){ref-type="fig"}B), but both treatment groups spent significantly more time in the top than controls (F = 30.13, p = 8.31 × 10^-8^, Figure [1](#F1){ref-type="fig"}B). Relatedly, fish treated with either isomer had a shorter latency to enter the top half of the tank relative to controls (F = 39.32, p = 5.5 × 10^-9^, Figure [1](#F1){ref-type="fig"}B) but there were no stereospecific effects (t = 0.39, p = 0.7, Figure [1](#F1){ref-type="fig"}B). Each fluoxetine isomer had minimal effects on locomotor activity (F = 0.22, p = 0.8, Figure [1](#F1){ref-type="fig"}B). Our data are consistent with the idea that given both fluoxetine isomers exhibit similar pharmacodynamics in inhibiting the serotonin transporter \[[@B6]-[@B10]\], there would be no predicted differences in anxiolytic effects. Fluoxetine, however, increases neurosteroid production (e.g. allopregnanolone) in a stereospecific manner and this has been proposed as an alternative mechanism of action for anxiolytics in mammals \[[@B14],[@B62]\]. Although we did not see any stereospecific anxiolytic effects of fluoxetine at the behavioral level, we have evidence that steroidogenic molecular pathways in the brain are over-represented with racemic treatment (Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, discussion below). Hence it is possible in zebrafish that some anxiolytic mechanisms of fluoxetine include alteration of both serotonin and neurosteroid levels.

###### 

Gene ontology analysis of differentially expressed genes

  **Gene ontology**                                                                            **FDR corrected p-value**                                                                                                              
  ------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ---------- ---------- ----------
  BP                                                                                            lipid metabolic process                                                                             GO:0006629   1.62E-03              6.01E-07
  BP                                                                                           lipid biosynthetic process                                                                           GO:0008610   8.22E-03              5.75E-05
  BP                                                                                          fatty acid metabolic process                                                                          GO:0006631   8.77E-03              2.21E-04
  BP                                                                                  very long-chain fatty acid metabolic process                                                                  GO:0000038   7.78E-03              1.99E-03
  BP                                                                                        fatty acid biosynthetic process                                                                         GO:0006633   1.09E-02              4.35E-04
  BP                                                                                very long-chain fatty acid biosynthetic process                                                                 GO:0042761   7.78E-03              1.99E-03
  BP                                                                                        small molecule metabolic process                                                                        GO:0044281   1.06E-02                  
  BP                                                                                         organic acid metabolic process                                                                         GO:0006082   1.56E-04   1.83E-02       
  BP                                                                                           oxoacid metabolic process                                                                            GO:0043436   1.56E-04   1.83E-02       
  BP                                                                                       carboxylic acid metabolic process                                                                        GO:0019752   5.22E-04   1.43E-02       
  BP                                                                                      single-organism biosynthetic process                                                                      GO:0044711   2.24E-03                  
  BP                                                                                      small molecule biosynthetic process                                                                       GO:0044283   1.93E-03                  
  BP                                                                                       organic acid biosynthetic process                                                                        GO:0016053   2.86E-04                  
  BP                                                                                      carboxylic acid biosynthetic process                                                                      GO:0046394   2.86E-04                  
  BP                                                                                           L-serine metabolic process                                                                           GO:0006563   2.66E-02   2.66E-03       
  BP                                                                                   organonitrogen compound metabolic process                                                                    GO:1901564              4.70E-02       
  BP                                                                                  organonitrogen compound biosynthetic process                                                                  GO:1901566              1.88E-02       
  BP                                                                                     cellular amino acid metabolic process                                                                      GO:0006520              2.27E-03       
  BP                                                                                    cellular amino acid biosynthetic process                                                                    GO:0008652              2.54E-02       
  BP                                                                                     alpha-amino acid biosynthetic process                                                                      GO:1901607              1.66E-02       
  BP                                                                                 serine family amino acid biosynthetic process                                                                  GO:0009070              6.35E-03       
  BP                                                                                               response to virus                                                                                GO:0009615              3.05E-03       
  BP                                                                                     monocarboxylic acid metabolic process                                                                      GO:0032787                         2.07E-03
  BP                                                                                    monocarboxylic acid biosynthetic process                                                                    GO:0072330                         2.60E-03
  BP                                                                                           steroid metabolic process                                                                            GO:0008202                         4.99E-02
  BP                                                                                        cellular lipid metabolic process                                                                        GO:0044255                         4.82E-03
  BP                                                                                            sterol metabolic process                                                                            GO:0016125                         1.21E-02
  MF                                                                                             phosphorylase activity                                                                             GO:0004645   4.24E-02              7.31E-03
  MF                                                                                        glycogen phosphorylase activity                                                                         GO:0008184   1.72E-02              2.95E-03
  MF                                                                                                cofactor binding                                                                                GO:0048037   3.24E-02                  
  MF                                                                                               catalytic activity                                                                               GO:0003824   3.19E-02                  
  MF                                                                                            oxidoreductase activity                                                                             GO:0016491   2.96E-03              1.43E-03
  MF                                                                            oxidoreductase activity, acting on CH-OH group of donors                                                            GO:0016614                         8.66E-03
  MF                                                                                 transferase activity, transferring acyl groups                                                                 GO:0016746                         9.02E-03
  MF                   oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NADH or NADPH as one donor, and incorporation of one atom of oxygen   GO:0016709                         2.47E-02

*BP* Biological Process, *MF* Molecular Function, *DEG* all differentially expressed genes. Blank cells indicate p \> 0.05.

###### 

KEGG pathway analysis of differentially expressed genes

  **KEGG Pathway**                                 **FDR corrected p-value**
  ---------------------------------------------- ---------------------------
  Fatty acid elongation                                             2.21E-02
  Metabolic pathways                                                5.11E-04
  Arachidonic acid metabolism                                       1.98E-03
  Synthesis and degradation of ketone bodies                        1.08E-02
  Terpenoid backbone biosynthesis                                   4.36E-03
  Glycine, serine and threonine metabolism                          2.77E-02
  Metabolism of xenobiotics by cytochrome P450                      6.78E-03
  Steroid biosynthesis                                              1.96E-09
  Steroid hormone biosynthesis                                      1.27E-03

Changes in gene expression consistent with alterations in stress and anxiety levels
-----------------------------------------------------------------------------------

Neuropeptides have modulatory roles in a variety of behaviors including stress and anxiety. RNA-sequencing analysis showed that several neuropeptides associated with stress and anxiety in other studies were differentially regulated with racemic fluoxetine treatment and validated with qRT-PCR (Figure [2](#F2){ref-type="fig"}). Isotocin (*oxtl*, RNA-sequencing: test statistic = -3.74, p = 0.014; qRT-PCR: p = 0.034) and neuropeptide Y (*npy*, test statistic = -5.37, p = 1.8 × 10^-5^; qRT-PCR: p = 0.045) showed significantly higher expression in fluoxetine treated fish relative to controls (Figure [2](#F2){ref-type="fig"}A, B). While isotocin is homologous to the mammalian oxytocin, relatively little is known about isotocin's behavioral functions in fishes \[[@B63]\]. In wild-type zebrafish, peripheral isotocin injection decreased the level of fear response to a predator in a dose-dependent manner \[[@B64]\], which suggests an anxiolytic effect. In rodents, pharmacological manipulations, gene expression, and transgenic animal studies have shown increases in oxytocin and NPY levels are associated with reduced anxiety \[[@B65]-[@B72]\]. Oxytocin is thought to affect many social behaviors in humans \[[@B73]\] including having anxiolytic effects \[[@B74],[@B75]\]. Interestingly, variants of NPY in humans are associated with anxiety susceptibility \[[@B76]\] and zebrafish may be an ideal system to explore this further.

![**RNA-sequencing and qRT-PCR expression of select genes with racemic fluoxetine treatment.** Gene expression of (**A**) isotocin, (**B**) neuropeptide Y, (**C**) urocortin 3, and (**D**) prolactin. In each panel left and right graphs represent quantification from RNA-sequencing (fragments per kilobase per million reads, FPKM) and qRT-PCR (expression ratio: gene expression in fluoxetine treatment / control), respectively. qRT-PCR gene expression was normalized to a housekeeping gene. Grey and white bars represent control and fluoxetine treatment, respectively. Error bars represent 95% confidence intervals. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001.](1471-2164-14-348-2){#F2}

Anxiety-related behavioral displays are often associated with a physiological stress response. The stress response in teleosts has been well-described \[[@B77],[@B78]\] and the molecular mechanisms underlying the cortisol stress response in zebrafish are similar to mammals \[[@B33],[@B79]\]. While we did not measure corticosteroid levels, the first study administering fluoxetine to domesticated zebrafish in the same paradigm used in this study found reduced whole-body cortisol levels compared to controls \[[@B11]\]. At the molecular level, urocortin 3 (*ucn3l*, part of the corticotrophin-releasing hormone family) and prolactin (*prl2*) were down-regulated with fluoxetine treatment in both RNA-sequencing (*ucn3l*: test statistic = 3.99, p = 0.006; *prl2*: test statistic = 5.35, p = 1.98 × 10^-5^; Figure [2](#F2){ref-type="fig"}C, D) and qRT-PCR analyses (*ucn3l* and *prl2*, p \< 0.001, Figure [2](#F2){ref-type="fig"}C, D). Urocortin 1-3 interact with the corticotrophin system in the brain by binding to the same receptors and can alter stress and anxiety \[[@B80]-[@B83]\]. Specifically, central administration of urocortins has been shown to be anxiogenic in rats \[[@B84]-[@B88]\]. The exact role of urocortin 3 in mediating stress and anxiety is not well understood as pharmacological and knock-out studies in rodents produce inconsistent results \[[@B89]-[@B91]\]. Prolactin in the brain is often associated with maternal behavior, but it is also associated with stress coping \[[@B92]-[@B94]\]. Other teleosts displayed elevated plasma prolactin levels in response to stress \[[@B95],[@B96]\], which is consistent with our results where treatment with an anxiolytic reduced *prl2* expression. It should be noted that for the gene expression parts of this study, we did not induce stress prior to brain extraction and this may explain why more genes associated with a stress response were not differentially regulated (Additional file [4](#S4){ref-type="supplementary-material"}: Table S2). Hence the reduction of *ucn3l* and *prl2* expression compared to the controls is consistent with the fluoxetine-treated fish having lower basal stress levels.

Neurotransmitter transporters have an important role in maintaining neural activity. The gene coding for the GABA transporter, *slc6a11*, was significantly down-regulated in fluoxetine treated fish with RNA-sequencing (test statistic = 6.06, p = 4.49 × 10^-7^, Figure [3](#F3){ref-type="fig"}A). Alteration of GABA mediated signaling is one proposed causal mechanism of anxiety and GABA transporter knockout mice exhibit reduced anxiety- and depression-related behaviors \[[@B97]\]. Hence, lower expression of GABA transporter is consistent with the finding that fluoxetine treated fish had reduced stress and anxiety-related behaviors. qRT-PCR validation showed mixed results where normalizing to a housekeeping gene showed significant differences between groups (p = 0.035, Figure [3](#F3){ref-type="fig"}A) but normalizing to total RNA did not (t = 1.34, p = 0.096, Additional file [3](#S3){ref-type="supplementary-material"}: Figure S2). The serotonin transporters (*slc6a4a* and *slc6a4b*) showed no differences in expression between groups by RNA-sequencing (*slc6a4a*: test statistic = 0.957, p = 0.855; *slc6a4b*: test statistic = 0.86, p = 0.876; Figure [3](#F3){ref-type="fig"}B, C) or qRT-PCR (*slc6a4a*: p = 0.058; *slc6a4b*: p = 0.242; Figure [3](#F3){ref-type="fig"}B, C). This is consistent with other studies in teleosts and rodents where chronic fluoxetine treatment altered expression of genes other than the serotonin transporter \[[@B42],[@B98]-[@B101]\]. SSRIs bind to serotonin transporters to inhibit their function, however, SSRIs may not regulate the expression of the transporter. Although several microarray studies focusing on a specific brain region did not show significant differences in expression of the serotonin transporter gene with fluoxetine treatment \[[@B98]-[@B101]\], we cannot rule out brain region specific regulation in zebrafish. Two genes (*isg15*, *nrbf2*) showed greater than two fold differences in expression between groups in RNA-sequencing (Figure [3](#F3){ref-type="fig"}D, E, Additional file [4](#S4){ref-type="supplementary-material"}: Table S2) but were not validated by qPCR (*isg15*: p = 0.1; *nrbf2*: p = 0.072). The housekeeping gene, elongation factor 1-alpha (*ef1a*) showed no significant difference between groups in either RNA-sequencing (test statistic = 0.258, p = 0.976, Figure [3](#F3){ref-type="fig"}F) or qRT-PCR (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S2). Overall, 80% of the genes we examined by qRT-PCR showed consistent expression patterns as RNA-sequencing, which is a rate consistent with other transcriptome studies \[[@B102],[@B103]\]. There was a trend for a positive correlation between RNA-sequencing and qRT-PCR expression levels across all genes (n = 10, r = 0.49, p = 0.072). However, when excluding genes (*isg15*, *nrbf2*) that did not show consistent expression patterns between RNA-sequencing and qRT-PCR, there was a significant positive correlation (n = 8, r = 0.88, p = 0.002).

![**RNA-sequencing and qRT-PCR expression of select genes with racemic fluoxetine treatment.** Gene expression of (**A**) GABA transporter, (**B**) serotonin transporter A, (**C**) serotonin transporter B, (**D**) ISG15 ubiquitin-like modifier, (**E**) nuclear receptor binding factor 2, and (**F**) elongation factor 1-alpha. In each panel left and right graphs represent quantification from RNA-sequencing (fragments per kilobase per million reads, FPKM) and qRT-PCR (expression ratio: gene expression in fluoxetine treatment / control), respectively. qRT-PCR gene expression was normalized to a housekeeping gene. Grey and white bars represent control and fluoxetine treatment, respectively. Error bars represent 95% confidence intervals. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001.](1471-2164-14-348-3){#F3}

Identification of global transcriptome changes and related pathways
-------------------------------------------------------------------

Of the 26,585 protein-coding genes analyzed, 411 were differentially regulated with racemic fluoxetine treatment (Figure [4](#F4){ref-type="fig"}, Additional file [4](#S4){ref-type="supplementary-material"}: Table S2). In racemic fluoxetine treated fish, 167 and 244 genes were up- and down-regulated, respectively. Gene ontology (GO) analysis of all differentially expressed genes reveal that terms related to lipid (p = 0.001) and small molecule metabolism (p = 0.01) were significantly over-enriched (Table [1](#T1){ref-type="table"}). Interestingly when we accounted for direction of expression in the GO analysis, amino acid and lipid metabolic processes were up-regulated and down-regulated, respectively, with fluoxetine treatment (Table [1](#T1){ref-type="table"}). These data suggest that male zebrafish treated with fluoxetine (i.e., reduced anxiety and stress levels) may be shifting macromolecule resources from energy (e.g. lipid) to enzymatic (e.g. amino acid) processes in the brain. It is well known that individuals will change foraging habits in the presence of predators \[[@B104],[@B105]\] and it is plausible that less anxious zebrafish seek out foods higher in protein content. While we fed the fluoxetine-treated and control groups *ad libitum* future studies should assess for differences in food consumption or diet preference. An equally likely hypothesis is that individuals with higher stress and anxiety levels have disrupted neurosteroid levels - possibly due to altered precursor activity. Of note, fish used in this study were selectively bred to exhibit high levels of stress and anxiety behaviors and hence control fish are presumed to have high levels of stress and anxiety \[[@B29]\]. Highly stressed and anxious (e.g., control) fish have up-regulated lipid and steroid metabolism (Table [1](#T1){ref-type="table"}) that may lead to altered neurosteroid production (via precursor availability). We acknowledge that transcriptome wide patterns are challenging to interpret and in this study we can only speculate on the precise roles of lipid and amino acid metabolism in stress and anxiety. It is also possible that by utilizing the whole brain, we may not be able to detect some pathways that are differentially expressed in specific regions. It should be noted, however, that whole-brain transcriptome studies still provide important insights into the molecular mechanisms of sex differences and a variety of social behaviors \[[@B56],[@B106]-[@B114]\]. Future studies should use transgenic zebrafish or pharmacologically alter expression levels to better characterize the role of a gene. Complementary studies could also assess localized differential expression patterns of "candidate" genes across the brain via neurohistochemical techniques \[[@B115]-[@B117]\] to assist in identifying candidate brain regions for transcriptomic analyses. Alternatively, using zebrafish with naturally high and low stress and anxiety-related behavioral levels (e.g., HSB, LSB \[[@B29]\]) will provide an opportunity to test for similar sorts of transcriptome changes in a non-pharmacological context and is currently underway in our laboratory.

![**Volcano plot of all protein-coding genes analyzed by RNA-sequencing.** Genes differentially expressed with p \< 0.05 after correcting for false discovery rate are in orange. Genes with a p \> 0.05 after correcting for false discovery rate are in black. Any point above 15 on the y-axis has a p \< 5 x 10^-15^.](1471-2164-14-348-4){#F4}

Using an alternative database to analyze global transcriptome changes that has associations with pathways, Kyoto Encyclopedia of Genes and Genomes (KEGG \[[@B118],[@B119]\]), resulted in largely similar over-represented pathways as GO analysis (Table [2](#T2){ref-type="table"}). Amino acid pathways (glycine, serine, and threonine, p = 5.11 × 10^-4^) and lipid related pathways (fatty acid elongation, p = 0.022) were over-represented (Table [2](#T2){ref-type="table"}). Notably, steroid (p = 1.96 × 10^-9^) and steroid hormone (p = 0.001) biosynthesis pathways were also over-represented (Table [2](#T2){ref-type="table"}). While we did not measure steroid levels in this study, in male goldfish treated with fluoxetine, there was an increase in estradiol, decrease in testosterone, and no changes in luteinizing or growth hormone serum levels but how these changes relate to anxiety-related behaviors was not discussed \[[@B120]\]. Neurosteroids (e.g. allopregnanolone) are implicated as potential mediators of anxiety in mammals \[[@B13]-[@B15],[@B18],[@B121]\]. Fluoxetine can increase neurosteroid content and S-fluoxetine increases allopregnanolone levels more effectively than the R isomer \[[@B13],[@B14],[@B21]\]. Allopregnanolone reduces anxiety in rodents and has a similar efficacy as fluoxetine \[[@B122]-[@B125]\]. As we see reduction in anxiety-related behaviors (Figure [1](#F1){ref-type="fig"}) and over-representation of steroid hormone pathways (Table [2](#T2){ref-type="table"}) in the brain with fluoxetine treatment, it is possible that the anxiolytic effects seen in this study are due to changes in neurosteroid content.

Few studies have examined transcriptome level changes in gene expression with fluoxetine treatment in teleosts. One study has examined the effects of fluoxetine treatment on differential gene expression in whole body larval zebrafish through microarrays \[[@B42]\]. Of genes we found differentially expressed in adult male whole-brain zebrafish, only three of these genes (*fkbp5*, *itm2cb*, and an unannotated gene) were also differentially expressed in larval zebrafish \[[@B42]\]. Fluoxetine is known to have age-dependent effects in mammals and it is possible that we are observing molecular evidence of this in zebrafish \[[@B126]-[@B128]\]. It should be noted though, that changes in membrane protein activity and/or composition (e.g. *fkbp5*, *itm2cb*) may be a common mechanism of fluoxetine action across the lifecycle. Interestingly, in a microarray study identifying hypothalamic differential gene expression in female goldfish treated with fluoxetine, we observed only three genes (*trib3*, *oxtl*, *mbpb*) that were similarly differentially regulated in our study. It is possible that this minimal amount of overlap between lists of genes differentially regulated is due to sex or regional specificity. Hypothalamic isotocin levels decreased with fluoxetine treatment in female goldfish \[[@B98]\] but showed no expression differences in male telencephalon \[[@B120]\]. It should be noted that neither of the studies utilizing fluoxetine-treated goldfish \[[@B98],[@B120]\] or larval zebrafish \[[@B42]\] measured anxiety-related behavior. Surprisingly, the lack of a large overlap of differentially expressed genes with fluoxetine treatment was also found between mice and rats with genomic analyses \[[@B99]-[@B101]\]. While there may be species- and brain region-specific effects of fluoxetine, uncovering potential universal mechanisms of action of fluoxetine will need to utilize a more comprehensive comparative approach.

Conclusions
===========

In this study we present data from both behavioral and molecular levels showing that fluoxetine alters stress and anxiety-related behaviors in wild-derived male zebrafish. Racemic and stereoisomers of fluoxetine reduce anxiety-related behaviors as indicated by drug treated fish spending more time in the top half of the tank. There were no stereoisomer effects on behavior but these effects were not tested at the molecular levels where it is possible that GABAergic and serotonergic activity were altered. In the small sampling of "candidate" neuropeptides (*npy*, *oxtl*, *prl2*, *ucn3l*) linked to stress and anxiety in the literature, our gene expression results were consistent with fluoxetine-induced changes at the molecular level in other model systems. Larger scale analyses reveal that lipid and amino acid metabolic processes and steroid biosynthesis are disproportionately influenced. Changes in lipid, amino acid and neurosteroid utilization in the brain may be characteristic of fluoxetine treatment and, by extension, stress and anxiety.
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###### Additional file 1: Figure S1

Fluoxetine dose-response curve. Time spent on the top half of the tank (y-axis) for fish treated with 0, 11, 33, and 100 μg/L racemic fluoxetine (x-axis). N = 6 at each concentration.
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###### Additional file 2: Table S1

qRT-PCR primer characteristics.
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###### Additional file 3: Figure S2

qRT-PCR validation of expression of select genes with racemic fluoxetine treatment. Genes examined are (A) isotocin, (B) neuropeptide Y, (C) urocortin 3, (D), prolactin, (E) GABA transporter, (F) serotonin transporter A, (G) serotonin transporter B, (H) ISG15 ubiquitin-like modifier, (I) nuclear receptor binding factor 2, and (J) elongation factor 1-alpha. Gene expression values are normalized to total RNA input. Error bars represent standard error. \*, p \< 0.05; \*\*; \*\*\*, p \< 0.001; +, data is consistent with RNA-sequencing results.
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###### Additional file 4: Table S2

Significant differentially expressed genes with fluoxetine treatment after correcting for false discovery rate.
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